Core Viewpoint - Zhaoke Ophthalmology-B (06622) has expanded its global commercialization rights for its core presbyopia treatment drug BRIMOCHOL™ PF to Singapore and Vietnam, enhancing its market presence in eight countries [1] Group 1: Company Developments - Zhaoke Ophthalmology has granted exclusive commercialization rights for BRIMOCHOL™ PF to AFT Pharmaceuticals in Singapore and to Santen Pharmaceutical in Vietnam [1] - The company’s global commercial footprint now includes South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan, Singapore, and Vietnam [1] Group 2: Partner Companies - AFT Pharmaceuticals is a multinational pharmaceutical company based in New Zealand, focusing on developing and licensing products in over 125 countries [1] - Santen Pharmaceutical is a Japan-based private pharmaceutical company with a strong emphasis on research and development, particularly in the ophthalmology sector [1]
港股异动 | 兆科眼科-B(06622)盘中涨超7% 公司扩大与AFT的合作至新加坡 与千寿达成越南合作协议